We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

24 hedge funds and large institutions have $3.16M invested in Moleculin Biotech in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

4% more funds holding

Funds holding: 23 → 24 (+1)

0% more ownership

Funds ownership: 0.03% → 0.03% (+0%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

27% less capital invested

Capital invested by funds: $4.32M → $3.16M (-$1.16M)

Holders
24
Holders Change
+1
Holders Change %
+4.35%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$30.7K
2
Citadel Advisors
Citadel Advisors
Florida
+$20.8K
3
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$16.8K
4
UBS Group
UBS Group
Switzerland
+$13.9K
5
TRCT
Tower Research Capital (TRC)
New York
+$8.69K

Top Sellers

Rank Fund Capital Flow
1
Charles Schwab
Charles Schwab
California
-$46K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$17K
3
Renaissance Technologies
Renaissance Technologies
New York
-$5.79K
4
BlackRock
BlackRock
New York
-$3.48K
5
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.14M – – –
SCM
2
Sio Capital Management
New York
$1.1M – – –
BlackRock
3
BlackRock
New York
$278K -$3.48K -6 -0.8%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$261K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$90K -$5.79K -10 -4%
State Street
6
State Street
Massachusetts
$76K – – –
SPC
7
Sigma Planning Corp
Michigan
$61K – – –
Northern Trust
8
Northern Trust
Illinois
$49K – – –
Jane Street
9
Jane Street
New York
$21K +$30.7K +53 New
JE
10
JMAC Enterprises
Pennsylvania
$14K – – –
Citadel Advisors
11
Citadel Advisors
Florida
$14K +$20.8K +36 New
Envestnet Asset Management
12
Envestnet Asset Management
Illinois
$12K +$16.8K +29 New
UBS Group
13
UBS Group
Switzerland
$11K +$13.9K +24 +600%
TRCT
14
Tower Research Capital (TRC)
New York
$10K +$8.69K +15 +136%
Bank of America
15
Bank of America
North Carolina
$7K – – –
Morgan Stanley
16
Morgan Stanley
New York
$6K – – –
Osaic Holdings
17
Osaic Holdings
Arizona
$4K – – –
CFO
18
CVA Family Office
Colorado
$1K – – –
Rockefeller Capital Management
19
Rockefeller Capital Management
New York
$1K – – –
AIP
20
Almanack Investment Partners
Pennsylvania
$1K +$1.74K +3 New
APA
21
American Portfolios Advisors
New York
$354 – – –
Charles Schwab
22
Charles Schwab
California
– -$46K -84 Closed
Two Sigma Advisers
23
Two Sigma Advisers
New York
– -$17K -31 Closed
CAPTRUST Financial Advisors
24
CAPTRUST Financial Advisors
North Carolina
– -$1K -1 Closed
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
– +$579 +1 New

MBRX Hedge Fund Activity: Q3 2022 in Review

24 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2022, worth a combined $3.16M — down 27% from $4.32M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new MBRX positions and 3 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $30.7K. The largest seller was Charles Schwab, exiting entirely with an estimated $46K sold.

  • 24 institutional investors held Moleculin Biotech (MBRX) as of Q3 2022, up from 23 in Q2 2022.
  • Funds reported $3.16M of Moleculin Biotech stock for Q3 2022, down 27% quarter-over-quarter.
  • 5 funds opened new Moleculin Biotech positions in Q3 2022 and 3 closed out, a net change of +2 holders.
  • The largest Moleculin Biotech buyer in Q3 2022 was Jane Street, an estimated $30.7K added.
  • The largest Moleculin Biotech seller in Q3 2022 was Charles Schwab, an estimated $46K sold.

Based on aggregated 13F filings for Q3 2022.